APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine Polyvalent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal Vaccine Polyvalent Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Polyvalent Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Polyvalent Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Polyvalent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Polyvalent Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Polyvalent Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Vaccine Polyvalent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Vaccine Polyvalent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumococcal Vaccine Polyvalent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumococcal Vaccine Polyvalent market include Merck & Co. and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal Vaccine Polyvalent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Vaccine Polyvalent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Vaccine Polyvalent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Vaccine Polyvalent market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Vaccine Polyvalent Segment by Company

Merck & Co.

Pfizer

Pneumococcal Vaccine Polyvalent Segment by Type

Prevnar 13

Pneumovax23

Pneumococcal Vaccine Polyvalent Segment by Application

65 Years and Older

19 To 64 Years Old

18 Years and Younger

Pneumococcal Vaccine Polyvalent Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pneumococcal Vaccine Polyvalent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumococcal Vaccine Polyvalent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal Vaccine Polyvalent significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal Vaccine Polyvalent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine Polyvalent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine Polyvalent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine Polyvalent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Vaccine Polyvalent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Vaccine Polyvalent industry.

Chapter 3: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumococcal Vaccine Polyvalent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumococcal Vaccine Polyvalent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Vaccine Polyvalent Industry Trends Table 2. Pneumococcal Vaccine Polyvalent Industry Drivers Table 3. Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges Table 4. Pneumococcal Vaccine Polyvalent Industry Restraints Table 5. Global Pneumococcal Vaccine Polyvalent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Vaccine Polyvalent Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal Vaccine Polyvalent Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Company (2021-2026) Table 9. Global Pneumococcal Vaccine Polyvalent Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pneumococcal Vaccine Polyvalent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumococcal Vaccine Polyvalent Key Company Manufacturing Base & Headquarters Table 12. Global Pneumococcal Vaccine Polyvalent Company, Product Type & Application Table 13. Global Pneumococcal Vaccine Polyvalent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Vaccine Polyvalent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Prevnar 13 Table 18. Significant Companies of Pneumovax23 Table 19. Global Pneumococcal Vaccine Polyvalent Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Pneumococcal Vaccine Polyvalent Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Pneumococcal Vaccine Polyvalent Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Type (2021-2026) Table 23. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Type (2027-2032) Table 24. Global Pneumococcal Vaccine Polyvalent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pneumococcal Vaccine Polyvalent Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pneumococcal Vaccine Polyvalent Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Type (2021-2026) Table 28. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Type (2027-2032) Table 29. Significant Companies of 65 Years and Older Table 30. Significant Companies of 19 To 64 Years Old Table 31. Significant Companies of 18 Years and Younger Table 32. Global Pneumococcal Vaccine Polyvalent Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global Pneumococcal Vaccine Polyvalent Sales Volume by Application (2021-2026) & (W Units) Table 34. Global Pneumococcal Vaccine Polyvalent Sales Volume by Application (2027-2032) & (W Units) Table 35. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Application (2021-2026) Table 36. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Application (2027-2032) Table 37. Global Pneumococcal Vaccine Polyvalent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pneumococcal Vaccine Polyvalent Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Pneumococcal Vaccine Polyvalent Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Application (2021-2026) Table 41. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Application (2027-2032) Table 42. Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2026) & (W Units) Table 44. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2021-2026) Table 45. Global Pneumococcal Vaccine Polyvalent Sales by Region (2027-2032) & (W Units) Table 46. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2027-2032) Table 47. Global Pneumococcal Vaccine Polyvalent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Pneumococcal Vaccine Polyvalent Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Region (2021-2026) Table 50. Global Pneumococcal Vaccine Polyvalent Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Region (2027-2032) Table 52. Global Pneumococcal Vaccine Polyvalent Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Pneumococcal Vaccine Polyvalent Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Pneumococcal Vaccine Polyvalent Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global Pneumococcal Vaccine Polyvalent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026) & (W Units) Table 57. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2021-2026) Table 58. Global Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032) & (W Units) Table 59. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2027-2032) Table 60. Global Pneumococcal Vaccine Polyvalent Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Pneumococcal Vaccine Polyvalent Sales Value Market Share by Country (2021-2026) Table 62. Global Pneumococcal Vaccine Polyvalent Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Pneumococcal Vaccine Polyvalent Sales Value Market Share by Country (2027-2032) Table 64. Merck & Co. Company Information Table 65. Merck & Co. Business Overview Table 66. Merck & Co. Pneumococcal Vaccine Polyvalent Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio Table 68. Merck & Co. Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Pneumococcal Vaccine Polyvalent Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio Table 73. Pfizer Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Pneumococcal Vaccine Polyvalent Distributors List Table 77. Pneumococcal Vaccine Polyvalent Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Polyvalent Product Image Figure 2. Global Pneumococcal Vaccine Polyvalent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Vaccine Polyvalent Sales (2021-2032) & (W Units) Figure 5. Global Pneumococcal Vaccine Polyvalent Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pneumococcal Vaccine Polyvalent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Prevnar 13 Image Figure 10. Pneumovax23 Image Figure 11. Global Pneumococcal Vaccine Polyvalent Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Pneumococcal Vaccine Polyvalent Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Type (2021-2032) Figure 14. Global Pneumococcal Vaccine Polyvalent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pneumococcal Vaccine Polyvalent Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Type (2021-2032) Figure 17. 65 Years and Older Image Figure 18. 19 To 64 Years Old Image Figure 19. 18 Years and Younger Image Figure 20. Global Pneumococcal Vaccine Polyvalent Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global Pneumococcal Vaccine Polyvalent Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Application (2021-2032) Figure 23. Global Pneumococcal Vaccine Polyvalent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pneumococcal Vaccine Polyvalent Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Application (2021-2032) Figure 26. Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Pneumococcal Vaccine Polyvalent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Pneumococcal Vaccine Polyvalent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 31. North America Pneumococcal Vaccine Polyvalent Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Pneumococcal Vaccine Polyvalent Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 37. South America Pneumococcal Vaccine Polyvalent Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Pneumococcal Vaccine Polyvalent Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Pneumococcal Vaccine Polyvalent Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Prevnar 13
  • Pneumovax23
Applications
  • 65 Years and Older
  • 19 To 64 Years Old
  • 18 Years and Younger
Companies covered
  • Merck & Co.
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  4. 1.2.2 Global Pneumococcal Vaccine Polyvalent Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumococcal Vaccine Polyvalent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumococcal Vaccine Polyvalent Market Dynamics
  1. 2.1 Pneumococcal Vaccine Polyvalent Industry Trends
  2. 2.2 Pneumococcal Vaccine Polyvalent Industry Drivers
  3. 2.3 Pneumococcal Vaccine Polyvalent Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Polyvalent Industry Restraints
3 Pneumococcal Vaccine Polyvalent Market by Company
  1. 3.1 Global Pneumococcal Vaccine Polyvalent Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal Vaccine Polyvalent Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumococcal Vaccine Polyvalent Average Price by Company (2021-2026)
  5. 3.5 Global Pneumococcal Vaccine Polyvalent Company Ranking (2024-2026)
  6. 3.6 Global Pneumococcal Vaccine Polyvalent Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumococcal Vaccine Polyvalent Company Product Type and Application
  8. 3.8 Global Pneumococcal Vaccine Polyvalent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumococcal Vaccine Polyvalent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumococcal Vaccine Polyvalent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Vaccine Polyvalent Market by Type
  1. 4.1 Pneumococcal Vaccine Polyvalent Type Introduction
  2. 4.1.1 Prevnar 13
  3. 4.1.2 Pneumovax23
  4. 4.2 Global Pneumococcal Vaccine Polyvalent Sales Volume by Type
  5. 4.2.1 Global Pneumococcal Vaccine Polyvalent Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pneumococcal Vaccine Polyvalent Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pneumococcal Vaccine Polyvalent Sales Value by Type
  9. 4.3.1 Global Pneumococcal Vaccine Polyvalent Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pneumococcal Vaccine Polyvalent Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pneumococcal Vaccine Polyvalent Sales Value Share by Type (2021-2032)
5 Pneumococcal Vaccine Polyvalent Market by Application
  1. 5.1 Pneumococcal Vaccine Polyvalent Application Introduction
  2. 5.1.1 65 Years and Older
  3. 5.1.2 19 To 64 Years Old
  4. 5.1.3 18 Years and Younger
  5. 5.2 Global Pneumococcal Vaccine Polyvalent Sales Volume by Application
  6. 5.2.1 Global Pneumococcal Vaccine Polyvalent Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Vaccine Polyvalent Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pneumococcal Vaccine Polyvalent Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pneumococcal Vaccine Polyvalent Sales Value by Application
  10. 5.3.1 Global Pneumococcal Vaccine Polyvalent Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumococcal Vaccine Polyvalent Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pneumococcal Vaccine Polyvalent Sales Value Share by Application (2021-2032)
6 Pneumococcal Vaccine Polyvalent Regional Sales and Value Analysis
  1. 6.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Vaccine Polyvalent Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Vaccine Polyvalent Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal Vaccine Polyvalent Sales by Region (2027-2032)
  5. 6.3 Global Pneumococcal Vaccine Polyvalent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumococcal Vaccine Polyvalent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumococcal Vaccine Polyvalent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumococcal Vaccine Polyvalent Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumococcal Vaccine Polyvalent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  12. 6.6.2 North America Pneumococcal Vaccine Polyvalent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumococcal Vaccine Polyvalent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  21. 6.9.2 South America Pneumococcal Vaccine Polyvalent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal Vaccine Polyvalent Country-level Sales and Value Analysis
  1. 7.1 Global Pneumococcal Vaccine Polyvalent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal Vaccine Polyvalent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumococcal Vaccine Polyvalent Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumococcal Vaccine Polyvalent Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumococcal Vaccine Polyvalent Sales by Country (2027-2032)
  6. 7.4 Global Pneumococcal Vaccine Polyvalent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumococcal Vaccine Polyvalent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumococcal Vaccine Polyvalent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumococcal Vaccine Polyvalent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumococcal Vaccine Polyvalent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumococcal Vaccine Polyvalent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co.
  2. 8.1.1 Merck & Co. Company Information
  3. 8.1.2 Merck & Co. Business Overview
  4. 8.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolio
  6. 8.1.5 Merck & Co. Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Vaccine Polyvalent Value Chain Analysis
  2. 9.1.1 Pneumococcal Vaccine Polyvalent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Vaccine Polyvalent Sales Mode & Process
  6. 9.2 Pneumococcal Vaccine Polyvalent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Vaccine Polyvalent Distributors
  9. 9.2.3 Pneumococcal Vaccine Polyvalent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst